<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03837925</url>
  </required_header>
  <id_info>
    <org_study_id>2016-02</org_study_id>
    <nct_id>NCT03837925</nct_id>
  </id_info>
  <brief_title>Pharmaco-metabolomic Effects of Statins: METASTATINE</brief_title>
  <acronym>METASTATINE</acronym>
  <official_title>Pharmaco-metabolomic Effects of Statins: METASTATINE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fondation Coeur et Recherche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ICAN Nutrition Education and Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fédération francaise de cardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins are effective in cardio-vascular prevention by lowering LDL-Cholesterol levels but
      also through other mechanisms poorly understood. Our hypothesis is that some of these effects
      are mediated by microbiota alteration, leading to diminution of expression of microbiota
      derived pro-atherogenic metabolites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this prospective double blind placebo-controlled study is to evaluate the acute
      effects of statins on microbiota and its derived metabolites at 2 and 6 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>2 groups of patients having treatment or placebo</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Placebo manufactured as the treatment. Packaging identical.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of trimethylamine N-oxide trimethylamine oxide in blood, measured post-prandially at week-6 in atorvastatin arm and placebo arm.</measure>
    <time_frame>Week-6</time_frame>
    <description>The main objective of the study is to measure the direct effect of Hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors (Atorvastatin) on the production of atherogenic metabolites derived from intestinal microbiota</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of trimethylamine N-oxide trimethylamine oxide in blood, measured post-prandially at week-2 in atorvastatin arm and placebo arm.</measure>
    <time_frame>week-2</time_frame>
    <description>To evaluate the evolution of the whole circulating metabolomic profile linked to the introduction of statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of trimethylamine N-oxide trimethylamine oxide in blood, measured pre and post-prandially at week-2 and week-6 in atorvastatin arm.</measure>
    <time_frame>Week-2 and week-6</time_frame>
    <description>To evaluate changes in the microbiome related to the introduction of statins</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between W0, W2 and W6 after initiation of atorvastatin vs placebo of circulating metabolomic profile (pre- and postprandial)</measure>
    <time_frame>Week 2 and Week 6</time_frame>
    <description>To correlate changes in lipid parameters induced by statins with metabolomic and lipidemic changes and microbiome. Rate of 100 metabolites will be analysed, and gathered as follows:
metabolism of acylcarnitine (3), metabolism of bile acids (5), carbohydrate metabolism (1), dietary choline metabolism (3), metabolism of amino acids (34), vitamins and cofactors (7), metabolism of creatine (2), polyamine metabolism (3), purine metabolism (5), pyrimidine metabolism (9), tryptophan / kynurenine metabolism (21), caffeine metabolism (3), Citric Acid cycle (3), urea cycle (1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between W0, W2 and W6 after initiation of atorvastatin vs placebo of the microbiome</measure>
    <time_frame>Week 2 and Week 6</time_frame>
    <description>To analyze the influence of the microbiota on the variability of response to atorvastatin.
169/5000 The stool will be analyzed by metagenomic sequencing using the &quot;shot gun&quot; technique, a direct sequencing that quantifies the number of bacterial genes and annotates them.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>ATORVASTATIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Atorvastatin 40mg caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG, to evaluate the pharmaco-metabolomic effects of the Statine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo caps: one daily. 3 patient visits: inclusion / week 2 / week 6. At each visit, blood sampling, stool sampling, ECG to compare the pharmaco-metabolomic effects of the Statine between atorvastatin arm and placebo arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin 40mg Tablet</intervention_name>
    <description>Patient participation for 6 weeks of treatment</description>
    <arm_group_label>ATORVASTATIN</arm_group_label>
    <other_name>No other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo comparator</intervention_name>
    <description>Patient participation for 6 weeks of treatment</description>
    <arm_group_label>PLACEBO</arm_group_label>
    <other_name>No other name</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with cardiovascular risk requiring statins in primary prevention

          -  Contraception for women of childbearing age

        Exclusion Criteria:

          -  Previous antibiotics, proton pomp inhibitors, statins or other hypolipidemic drugs
             intake in the previous three months

          -  Renal insufficiency with creatinine clearance &lt;40ml/min

          -  Contra-indication to statins

          -  Previously known conditions affecting muscles, or digestive system

          -  Requirement of statins in secondary prevention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joe Elie SALEM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC 1421 CHU Pitie Salpetriere</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joe Elie SALEM, MD</last_name>
    <phone>33 1 42 17 85 32</phone>
    <email>joe-elie.salem@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alban DANSET, MD</last_name>
    <phone>33 1 42 17 85 33</phone>
    <email>alban.danset@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CIC La Sapétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joe Elie SALEM, MD</last_name>
      <phone>01 42 17 85 35</phone>
      <email>joe-elie.salem@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CIC HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne BLANCHARD, MD</last_name>
      <phone>01 56 09 29 44</phone>
      <email>anne.blanchard@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 12, 2019</study_first_posted>
  <last_update_submitted>June 17, 2019</last_update_submitted>
  <last_update_submitted_qc>June 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Statins</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>primary prevention microbiota</keyword>
  <keyword>metabolomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

